News | January 15, 2009

FDA Approves Trial on Radiation Therapy for Brain Stem Glioma

Jan 15, 2009 - The Burzynski Research Institute, Inc. (BRI), a biopharmaceutical company developing treatment for cancer based on genomic and epigenomic principles, reached an agreement with the FDA allowing the company to initiate a pivotal Phase III clinical trial of combination antineoplaston therapy plus radiation therapy in patients with newly-diagnosed, diffuse, intrinsic brainstem gliomas.

Antineoplaston therapy (ANP) uses a synthetic version of naturally occurring peptides and amino acid derivatives found in the human body to target and control cancer cells without destroying normal cells. The agreement was made under the FDA’s Special Protocol Assessment (SPA) procedure and means that the design and planned analysis of the Phase III study is acceptable to support a regulatory submission seeking new drug approval.

The primary objective of this randomized multicenter study is to compare overall survival of children with newly-diagnosed diffuse intrinsic brain stem glioma (DBSG) who receive combination antineoplaston therapy (Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)) plus radiation therapy (RT) versus RT alone.

DBSG are considered to be one of the most difficult types of cancer to treat. It combines highly malignant characteristics with the very difficult location of the brainstem. DBSG are inoperable because they involve most of the brainstem (diffuse and intrinsic). The number of children in the U.S. with brainstem gliomas is approximately 660. Absent treatment, the survival rate from time of diagnosis is six months or less.

At present, there are no standard curative treatments for the disease. RT is the only treatment that may slow its progress, but at two years 93 percent of children with this type of cancer die and none of them survive for five years. Other conventional treatments such as chemotherapy have generally been tried in clinical trials but are shown to be ineffective. There are no pharmacological treatments approved for DBSG at this time.
“We are very pleased by our agreement with the FDA to move forward with a confirmatory study on a type of tumor that has shown itself to be highly treatment resistant and challenged further by severely limited treatment options and clinical trials that could expand and discover new, efficacious therapies,” said Stanislaw R. Burzynski, M.D., Ph.D. “The SPA agreement puts antineoplaston therapy further down a straight path to regulatory approval, enabling the kind of study that should prove its merits as another option to cancer management.”

What is unique about the agreement to the oncology field is that BRI received the approval without financial backing from the government and without a major pharmaceutical partner.

For more information: www.burzynskiclinic.com

Related Content

New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
The novel nanoparticle is designed to enhance radiation killing of cancer cells in the radiation resistant low-oxygen tumor core

The novel nanoparticle is designed to enhance radiation killing of cancer cells in the radiation resistant low-oxygen tumor core. Credit: Wenpei Fan, LOMIN Laboratory, NIBIB.

News | Radiation Therapy | May 08, 2019
Radiation kills tumors by creating oxygen free radicals that damage the tumor DNA. However, the lack of oxygen in the...
Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation
News | Proton Therapy | May 02, 2019
IBA (Ion Beam Applications SA) recently announced the first Flash irradiation in an IBA proton therapy gantry treatment...
Artificial intelligence (AI) was again the hottest topic in radiology, with 11 of the top 20 pieces of content this month relating to AI. These images are a few of the AI technologies highlighted in ITN Editor's Choice video of the most innovative AI technologies highlighted at RSNA 2018.

Artificial intelligence (AI) was again the hottest topic in radiology, with 11 of the top 20 pieces of content this month relating to AI. These images are a few of the AI technologies highlighted in ITN Editor's Choice video of the most innovative AI technologies highlighted at RSNA 2018. 

Feature | May 01, 2019
May 1, 2019 — Here is the list of the most popular content on the Imaging Technology New (ITN) magazine webs
Pencil Beam Scanning Better Protects Children With Brain Tumors
News | Proton Therapy | May 01, 2019
A comparison of three types of radiotherapy for children's brain tumors suggests a type of proton therapy called pencil...
Researchers Identify Ways to Predict and Avoid Radiotherapy Side Effects
News | Radiation Therapy | April 30, 2019
New research has shown a combination of biological markers and certain genetic changes can predict radiation...